US 11066360
Human plasma kallikrein inhibitors
granted A61PA61P17/00A61P17/10
Quick answer
US patent 11066360 (Human plasma kallikrein inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Grant date
- Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61P, A61P17/00, A61P17/10, A61P7/00